Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
| ▸ | JAK1 | P23458 | 3/20 | 0.33 |
| ▸ | JAK3 | P52333 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19155416 | 0.88 | MAPK1 (0.35) | JAK2JAK1JAK3MAPK1 | |
| SCHEMBL24025969 | 0.75 | JAK2 (0.35) | JAK2JAK1JAK3MAPK1 | |
| SCHEMBL25718741 | 0.75 | IRAK4 (0.33) | — | |
| SCHEMBL18352331 | 0.74 | JAK2 (0.34) | JAK2JAK1JAK3MAPK1 | |
| SCHEMBL14795128 | 0.72 | JAK2 (0.46) | JAK2JAK1JAK3 | |
| SCHEMBL16797942 | 0.71 | JAK2 (0.45) | JAK2JAK1JAK3 | |
| SCHEMBL25099112 | 0.71 | MAPK1 (0.30) | JAK2JAK1JAK3MAPK1 | |
| SCHEMBL650183 | 0.69 | JAK3 (0.65) | JAK2JAK1JAK3 | |
| SCHEMBL2325947 | 0.66 | JAK3 (0.44) | JAK2JAK1JAK3 | |
| SCHEMBL18720827 | 0.65 | JAK3 (0.42) | JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246466-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | JAK2 60/4885JAK1 228/4885JAK3 295/4885 |
| US-10246466-B2 | Diaryl macrocycles as modulators of protein kinases | MAP3K20, LCK, MAP3K1 | JAK2 60/4885JAK1 228/4885JAK3 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.